Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TCV 309

Known as: TCV-309 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Abstract Platelet‐activating factor (PAF) is a potent inflammatory lipid mediator in peripheral tissues. However, its role in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2000
Highly Cited
2000
Sepsis and organ failure remain the main cause of death on the ICU. Sepsis is characterized by a severe inflammatory response, in… Expand
1998
1998
Infiltration of eosinophils into the lung lumen is a hallmark of allergic asthmatic inflammation. To reach the lung lumen… Expand
1997
1997
BACKGROUND Ischemia-reperfusion injury is one of the major problems in organ transplantation. The role of platelet-activating… Expand
1996
1996
In a prospective randomized, double-blind, placebo-controlled clinical study, the safety and efficacy of the platelet-activating… Expand
Highly Cited
1994
Highly Cited
1994
Platelet-activating factor (PAF) has been postulated to play a role in the pathogenesis of sepsis. Additionally, in vitro studies… Expand
1993
1993
1 The present study was conducted in order to examine the effects of the platelet‐activating factor (PAF) antagonist, TCV‐309… Expand
Highly Cited
1992
Highly Cited
1992
Pharmacological profiles of a novel specific platelet activating factor (PAF) antagonist, TCV-309 (3-bromo-5-[N-phenyl-N-[2-[2… Expand
1992
1992
TCV-309 potently and specifically inhibited the diverse biological actions of PAF such as platelet aggregation, hypotension… Expand
Highly Cited
1992
Highly Cited
1992
The importance of platelet activating factor in acute pancreatitis was examined by determining the tissue content of endogenous… Expand